Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks

• Status: Withdrawn
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether injections of ranibizumab into the eye are safe and well tolerated when given to subjects in multiple doses.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Illinois at Chicago
• Collaborator: Genentech, Inc.
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Ability to provide written informed consent and comply with study assessments for the full duration of the study

• Age > 18 years

• Angioid streaks

• Subfoveal CNV of recent onset with the following characteristics

• Absence of subfoveal fibrosis

• Fibrosis less than 25% of the lesion

• Presence of blood, subretinal fluid, and/or lipid

• New onset symptoms within 12 weeks

• Visual acuity 20/40 to 20/800 on an ETDRS chart

Exclusion Criteria:

• Prior treatment of subfoveal CNV in the study eye

• Age-related macular degeneration

• Uncontrolled glaucoma

• High myopia (> -10.00 D spherical equivalent)

• Prior retinal detachment

• Media opacity preventing adequate view of the retina

• Planned cataract surgery in the next 3 months

• Current chemotherapy for cancer

• Immunocompromised state

• Pregnancy (positive pregnancy test) or lactation

• Premenopausal women not using adequate contraception.

• Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated

• Participation in another simultaneous medical investigation or trial

• History of any previous treatment for angioid streaks